Zacks Analyst Blog Highlights: General Motors, CV Therapeutics, TranSwitch and Solectron.CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: General Motors (NYSE NYSE See: New York Stock Exchange : GM), CV Therapeutics (Nasdaq: CVTX), TranSwitch Corp. (Nasdaq: TXCC TXCC Transwitch Corporation (stock symbol) ) and Solectron (NYSE: SLR (1) (Scalable Linear Recording) A line of magnetic tape drives from Tandberg Data that evolved from the QIC Data Cartridge format. See QIC. (2) (Single Lens Reflex) A camera that uses the same lens for viewing and shooting. ). See the latest posts to the Analyst Blog by visiting: http://at.zacks.com/?id=2673. Here are highlights from Wednesday's Analyst Blog: Upgrading General Motors to Buy Management's introduction of the North American North American named after North America. North American blastomycosis see North American blastomycosis. North American cattle tick see boophilusannulatus. turnaround plan to mitigate the impact of the difficult industry conditions, its increased focus on the Asia/Pacific region, enhancement of the product portfolio and aggressive cost cutting are some of the positives of the General Motors (NYSE: GM) story. Kirk Kerkorian's divestment of his entire stake in GM has put a downward pressure on the stock price. This has also provided a challenge to Chairman and Chief Executive Office Rick Wagoner George Richard "Rick" Wagoner, Jr. (b. February 9 1953, Wilmington, Delaware) is Chairman and Chief Executive Officer of General Motors. Wagoner grew up in Richmond, Virginia and graduated from John Randolph Tucker High School there. to turn around the company. Going forward, we believe that the stock will perform well and thus, raise our recommendation to a Buy with a six-month target price of $32.00. Target $17 on CVTX Headquartered in Palo Alto, CA, CV Therapeutics (Nasdaq: CVTX) is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. Third quarter sales of Ranexa (launched in March for chronic angina) showed signs of improvement. However, uptake will probably remain low until the MERLIN data becomes available in the first quarter of 2007. Nevertheless, we continue to rate the shares a Buy based on our belief that MERLIN will be positive and use in the first-line indication and acute coronary syndrome acute coronary syndrome n. A sudden, severe coronary event that mimics a heart attack, such as unstable angina. acute coronary syndrome (ACS (Asynchronous Communications Server) See network access server. ) will drive significant profitably in 2010. We are raising our price target to $17. TranSwitch Burning Cash TranSwitch Corp. (Nasdaq: TXCC) is an OEM (Original Equipment Manufacturer) The rebranding of equipment and selling it. The term initially referred to the company that made the products (the "original" manufacturer), but eventually became widely used to refer to the organization that buys the products and of semiconductor devices used in telecommunications and data communications equipment See DCE. Data Communications Equipment - Data Communication Equipment . September quarter results exceeded consensus estimates. Revenue fell by 6.8% last quarter and is expected to be flat in the fourth quarter. Although it is experiencing a gradual improvement in its end-markets and a growing number of design wins, revenue growth in the second half of 2006 is expected to remain weak. The company continues to record losses while burning cash. We continue to rate shares of TXCC a Hold. This is a high-risk stock. Sell Rec Kept on Solectron While Solectron's (NYSE: SLR) "Lean" manufacturing initiatives should help keep operating expenses Operating expenses The amount paid for asset maintenance or the cost of doing business, excluding depreciation. Earnings are distributed after operating expenses are deducted. under control, current operating margins are well below its peer group, a condition that is unlikely to change without revenue growth. Until Solectron is able to demonstrate revenue growth through the ramp of new projects, we believe the stock will continue to underperform the market. We, therefore, rate the company Sell with a six-month price target of $2.50. See the latest posts to the Analyst Blog by visiting http://at.zacks.com/?id=2645. About Zacks Equity Research Zacks Equity Research provides the best of quantitative and qualitative analysis Qualitative Analysis Securities analysis that uses subjective judgment based on nonquantifiable information, such as management expertise, industry cycles, strength of research and development, and labor relations. to help investors know what stocks to buy and which to sell for the long-term. Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons. Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today by visiting http://at.zacks.com/?id=2674. About Zacks Zacks.com is a property of Zacks Investment Research Zacks Investment Research A firm that compiles earnings estimates and brokerage firm investment recommendations for thousands of publicly traded firms. , Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion